

Paul Martin

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

Company or Organization

Entity	Type	Interest Held By
Abgenomics	Grant / Contract	Other - Contract with institution for clinical trial
Enlivex Therapeutics	Consultant	Self
Genentech	Consultant	Self
Neovii	Consultant	Self
Pfizer	Data And Safety Monitoring	Self
Pharmacyclics LLC, An AbbVie Company	Consultant	Self
Procter and Gamble	Stock	Self
Xenikos	Grant / Contract	Other - Contract with institution for clinical trial

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- o Support of the submitted work at any time, from the initial conception and planning to the present;
- o A relevant financial activity outside the submitted work that was present in the past 36 months; or
- o A relationship or activity not covered above.

a. **Abgenomics**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

b. **Enlivex Therapeutics**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

c. **Genentech**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

d. **Neovii**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

e. **Pfizer**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

f. **Pharmacyclics LLC, An AbbVie Company**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

g. **Procter and Gamble**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

h. **Xenikos**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.

Ted Gooley

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- Support of the submitted work at any time, from the initial conception and planning to the present;
- A relevant financial activity outside the submitted work that was present in the past 36 months; or
- A relationship or activity not covered above.

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.

Steven Pergam

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

Company or Organization

Entity	Type	Interest Held By
Chimerix, Inc	Grant / Contract	Other - Institution
Global Life Technologies, Inc	Grant / Contract	Other - Institution
Merck	Grant / Contract	Other - Institution

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- o Support of the submitted work at any time, from the initial conception and planning to the present;
- o A relevant financial activity outside the submitted work that was present in the past 36 months; or
- o A relationship or activity not covered above.

a. **Chimerix, Inc**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

b. **Global Life Technologies, Inc**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

c. **Merck**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.



Stephanie Lee

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- Support of the submitted work at any time, from the initial conception and planning to the present;
- A relevant financial activity outside the submitted work that was present in the past 36 months; or
- A relationship or activity not covered above.

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.

Sangeeta Hingorani

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- Support of the submitted work at any time, from the initial conception and planning to the present;
- A relevant financial activity outside the submitted work that was present in the past 36 months; or
- A relationship or activity not covered above.

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.

Rainer Storb

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

Not known; George B. McDonald is the first and corresponding author

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- Support of the submitted work at any time, from the initial conception and planning to the present;
- A relevant financial activity outside the submitted work that was present in the past 36 months; or
- A relationship or activity not covered above.

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

Company or Organization

Entity	Type	Interest Held By
Celgene Corporation	Grant / Contract	Self
Jazz Pharmaceuticals	Consultant	Self
National Cancer Institute	Grant / Contract	Self

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

M19-2936

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- o Support of the submitted work at any time, from the initial conception and planning to the present;
- o A relevant financial activity outside the submitted work that was present in the past 36 months; or
- o A relationship or activity not covered above.

a. **Celgene Corporation**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

b. **Jazz Pharmaceuticals**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

c. **National Cancer Institute**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.



Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

Company or Organization

Entity	Type	Interest Held By
Lucent Medical Systems	Consultant	Spouse/Partner
Sangamo Therapeutics	Data And Safety Monitoring	Self
Soligenix Pharmaceuticals	Consultant	Self

Additional Information:

1. **Are you the corresponding author?**

Yes.

2. **What is the Manuscript Title?**

Survival, relapse, and non-relapse mortality after allogeneic hematopoietic cell transplantation: Comparing 2003-2007 vs. 2013-2017 cohorts

3. **What is the Manuscript Identifying Number (if you know it)?**

M19-2936

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- o Support of the submitted work at any time, from the initial conception and planning to the present;
- o A relevant financial activity outside the submitted work that was present in the past 36 months; or
- o A relationship or activity not covered above.

a. **Lucent Medical Systems**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

No relation to this manuscript.

b. **Sangamo Therapeutics**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

No relationship to this manuscript.

c. **Soligenix Pharmaceuticals**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

No relationship to this manuscript

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.



Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

Survival, Non-relapse mortality

3. **What is the Manuscript Identifying Number (if you know it)?**

M19-2936

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- **Support of the submitted work at any time, from the initial conception and planning to the present;**
- **A relevant financial activity outside the submitted work that was present in the past 36 months; or**
- **A relationship or activity not covered above.**

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.

Brenda Sandmaier

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Consultant	Spouse/Partner
Actinium Pharmaceuticals	Consultant	Self
AnaptysBio	Consultant	Spouse/Partner
AnaptysBio	Stock Option	Spouse/Partner
Blaze	Stock	Spouse/Partner
Bristol-Myers Squibb	Consultant	Self
Frazier Healthcare Ventures	Consultant	Spouse/Partner
Inipharm	Consultant	Spouse/Partner
Inipharm	Stock	Spouse/Partner
Kiadis Pharma	Consultant	Self
Mavupharma	Employment	Spouse/Partner
Mavupharma	Stock	Spouse/Partner
Oncoresponse	Consultant	Spouse/Partner
Oncoresponse	Stock	Spouse/Partner

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

M19-2936

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- o Support of the submitted work at any time, from the initial conception and planning to the present;
- o A relevant financial activity outside the submitted work that was present in the past 36 months; or
- o A relationship or activity not covered above.

a. **AbbVie**

- i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

Unrelated to current manuscript

b. **Actinium Pharmaceuticals**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

Unrelated to current manuscript

c. **AnaptysBio**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

Unrelated to current manuscript

d. **Blaze**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

Unrelated to current manuscript

e. **Bristol-Myers Squibb**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

Unrelated to current manuscript

f. **Frazier Healthcare Ventures**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

Unrelated to current manuscript

g. **Inipharm**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

Unrelated to current manuscript

h. **Kiadis Pharma**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

Unrelated to current manuscript

i. **Mavupharma**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

Unrelated to current manuscript

j. **Oncoresponse**

i. **Which of the three apply to this relationship or activity?**

Other relationship or activity not described above

ii. **Comments (Optional):**

Unrelated to current manuscript

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.

Marco Mielcarek

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- Support of the submitted work at any time, from the initial conception and planning to the present;
- A relevant financial activity outside the submitted work that was present in the past 36 months; or
- A relationship or activity not covered above.

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.

Guang-Shing Cheng

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- Support of the submitted work at any time, from the initial conception and planning to the present;
- A relevant financial activity outside the submitted work that was present in the past 36 months; or
- A relationship or activity not covered above.

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.

Michael Boeckh

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

Company or Organization

Entity	Type	Interest Held By
Allovir	Consultant	Self
Artemis Therapeutics	Consultant	Self
Astellas Pharma	Grant / Contract	Other - Fred Hutchinson Cancer Research Center
Astellas Pharma	Consultant	Self
Chimerix	Grant / Contract	Other - Fred Hutchinson Cancer Research Center
Chimerix	Consultant	Self
Gilead Sciences	Grant / Contract	Other - Fred Hutchinson Cancer Research Center
Gilead Sciences	Consultant	Self
GlaxoSmithKline	Consultant	Self
Helocyte	Other	Self
Merck	Grant / Contract	Self
Merck	Consultant	Self
Takeda Pharmaceutical	Grant / Contract	Other - Fred Hutchinson Cancer Research Center
Takeda Pharmaceutical	Consultant	Self
Vir Biotechnology	Grant / Contract	Other - Fred Hutchinson Cancer Research Center
Vir Biotechnology	Consultant	Self

Additional Information:

1. Are you the corresponding author?

No.

2. What is the Manuscript Title?

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. What is the Manuscript Identifying Number (if you know it)?

4. For each financial interest, you must indicate whether the interest or relationship represents:

- o Support of the submitted work at any time, from the initial conception and planning to the present;
- o A relevant financial activity outside the submitted work that was present in the past 36 months; or
- o A relationship or activity not covered above.

a. [Allovir](#)

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

b. **Artemis Therapeutics**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

c. **Astellas Pharma**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

d. **Chimerix**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

e. **Gilead Sciences**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

f. **GlaxoSmithKline**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

g. **Helocyte**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

h. **Merck**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

i. **Takeda Pharmaceutical**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

j. **Vir Biotechnology**

i. **Which of the three apply to this relationship or activity?**

Relevant financial activity outside the submitted work (present during the past 36 months)

ii. **Comments (Optional):**

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.



Mary Flowers

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

M19-2936

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- o Support of the submitted work at any time, from the initial conception and planning to the present;
- o A relevant financial activity outside the submitted work that was present in the past 36 months; or
- o A relationship or activity not covered above.

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

a. **Please describe the relationships/conditions/circumstances that are present.**

Pharmacyclics: Consultation Fresenius Kabi: Consultation Pharmacyclics: Research/Clin Trials in cGVHD Incyte & Novartis: Research/Clin trials in cGVHD Mallinckrodt, Astellas: Travel/Accommodation to attending meetings

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.

Frederick Appelbaum

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- Support of the submitted work at any time, from the initial conception and planning to the present;
- A relevant financial activity outside the submitted work that was present in the past 36 months; or
- A relationship or activity not covered above.

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.

Gary Schoch

Disclosure Purpose: Annals of Internal Medicine

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. **Are you the corresponding author?**

No.

2. **What is the Manuscript Title?**

:SURVIVAL, NON-RELAPSE MORTALITY, AND RELAPSE-RELATED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: COMPARING 2003-2007 VS. 2013-2017 COHORTS

3. **What is the Manuscript Identifying Number (if you know it)?**

4. **For each financial interest, you must indicate whether the interest or relationship represents:**

- Support of the submitted work at any time, from the initial conception and planning to the present;
- A relevant financial activity outside the submitted work that was present in the past 36 months; or
- A relationship or activity not covered above.

5. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

6. **Have you disclosed in the previous steps all relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

Certification

I certify that the information provided in this disclosure is complete and accurate, and I acknowledge that this disclosure form will be published by *Annals of Internal Medicine*.